Adjunctive Chinese Herbal Products Therapy Reduces the Risk of Ischemic Stroke Among Patients With Rheumatoid Arthritis

Hsuan-Shu Shen1,2, Jen-Huai Chiang3,4 and Nai-Huan Hsiung5*

1 Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, 2 School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan, 3 Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, 4 College of Medicine, China Medical University, Taichung, Taiwan, 5 Department of Nursing, Asia University, Taichung, Taiwan

We performed a retrospective cohort study to investigate the association between the risk of ischemic stroke (IS) and the use of Chinese herbal products (CHP) in combination with western medicine (WM) among patients with rheumatoid arthritis (RA). The data were sourced from the registry for beneficiaries, inpatient and ambulatory care claims, and Registry for Catastrophic Illness from the National Health Insurance Research Database (NHIRD) in Taiwan between 1997 and 2011. Patients, who were newly diagnosed with RA between 1997 and 2010, were classified as the CHP group or non-CHP group depending on the presence of absence the adjunctive use of CHP following a diagnosis of RA. A total of 4,148 RA patients were in both the CHP and non-CHP groups after 1:1 matching. Patients in the CHP group had a significantly lower risk of IS compared to patients in the non-CHP group (adjusted hazard ratio [aHR], 0.67; 95% confidence interval [CI], 0.52–0.86). In the CHP group, patients who used CHP for more than 30 days had a lower risk of IS than their counterparts (aHR: 0.61, 95% CI: 0.40–0.91). Gui-Zhi-Shao-Yao-Zhi-Mu-Tang, Shu-Jin-Huo-Xie-Tang, and Du-Huo-Ji-Sheng-Tang might be associated with a lower risk of IS. Finally, the use of CHP in combination with WM was associated with a decreased risk of IS in patients with RA, especially among those who had used CHP for more than 30 days. A further randomized control trial is required to clarify the casual relationship between these results.

Keywords: rheumatoid arthritis, ischemic stroke, Chinese herbal products, National Health Insurance Research Database, traditional Chinese medicine

INTRODUCTION

Patients with rheumatoid arthritis (RA) are at a greater risk of ischemic stroke (IS), which may be a leading cause of mortality and can lead to severe long-term disability (Benjamin et al., 2017). According to a meta-analysis study, the risk of stroke death was elevated by 52% among patients with RA (Avina-Zubieta et al., 2008). Danish and Taiwanese studies have also demonstrated that patients with RA were shown to have a 30% higher risk of IS compared to those without RA.
In addition to systemic chronic inflammation in individuals with RA, certain routinely prescribed medicines also increase the risk of IS (Nadareishvili et al., 2008; Lindhardsen et al., 2014). In accordance with the recommendations of the European League Against Rheumatism (EULAR), methotrexate, a kind of Disease-modifying antirheumatic drugs (DMARDs), plus short-term corticosteroids is the first-line therapy. When the treatment target cannot be achieved by methotrexate within 6 months or unfavorable prognostic factors are present, such as high disease activity, early erosion, or high level of rheumatoid factor, a TNF-antagonist may be considered as an add-on (Smolen et al., 2017). Previous research has documented that corticosteroids and certain non-steroidal anti-inflammatory drugs (NSAIDs) might increase the risk of IS in patients with RA 1.5- to 2-fold (Roubille et al., 2015). Methotrexate and TNF-antagonists, by contrast, are associated with the reduced risk of ischemic stroke (Tam et al., 2018). However, these drugs are associated with a potential risk of infection, fatigue, and liver damage (Salliot and van der Heijde, 2009). To avoid the side effects and debilitation associated with western medical treatment, the patients resorted to using traditional herbal remedies (Efthimiou and Kukar, 2010; Michalsen, 2013). Thus, nearly 30% of individuals with RA were also taking Chinese herbal medicine in a recent study (Huang et al., 2015). Some of commonly used polyherbal formulations or single herbs have been demonstrated anti-inflammatory action, these include Gui-Zhi-Yao-Zhi-Mu-Tang (contains Paonia lactiflora Pall., Atractylodes macrocephala Koidz., Anemarrhena asphodeloides Bge., Saposhnikovia divaricata (Turcz.) Schischk., Glycyrrhiza uralensis Fisch. ex DC., Cinnamomum cassia (L.) Presl, Epedphra sinica Stapf, Aconitum carmichaelii Debx., Zingiber officinal Roscoe) and Boswellia neglecta S.Moore (Ru-Xiang) (Ammon, 2006; Daily et al., 2017). Additionally, Tripterygium wilfordii Hook.f, Stephania tetrandra S Moore, and Zingiber officinale Roscoe have also been reported to have potential to suppress inflammation (Kang et al., 1996; Lacini et al., 2005; Wang et al., 2013). To date, most studies have purposely analyzed the effects of Chinese herbal products (CHP) in terms of alleviating the clinical symptoms and managing the chronic inflammation of patients with rheumatoid arthritis (Soeken et al., 2003; Zhang et al., 2011; Daily et al., 2017). However, there is a lack of studies that investigated whether the use of CHP was associated with a reduced risk of IS, which is a leading cause of death, in patients with RA. This study sought to evaluate the association between the use of CHP in combination with western medicine (WM) and the risk of IS in patients with RA by undertaking a large-scale retrospective cohort study.

**MATERIALS AND METHODS**

**Data Source**

This study used reimbursement claims data from the Taiwan National Health Insurance Program. A national health insurance (NHI) program was implemented in March 1995, which covers 22.6 million individuals out of the total population of 23.0 million in Taiwan. The NHI is an obligatory universal health insurance program, which offers comprehensive medical care coverage to 99% of the entire Taiwanese population and has contracts with 97% of the hospitals and clinics there (http://www.nhi.gov.tw/english/index.aspx). The National Health Insurance Research Database (NHIRD) covers every medical record including Traditional Chinese medicine treatment that is reimbursed by the NHI.

The datasets used in the study consisted of a registry for beneficiaries, inpatient, and ambulatory care claims, and the Registry for Catastrophic Illness from the NHIRD. Ambulatory care claims contain the individuals’ gender, date of birth, date of visit, codes for the International Classification of Disease, Ninth Revision, and Clinical Modification (ICD-9-CM) codes for three primary diagnoses. Inpatient claims contain ICD-9-CM codes for principal diagnosis up to a total of four secondary diagnoses. The registry for Catastrophic Illness database contains data from insurers who suffer from major diseases and are granted exemption from co-payment. A disease diagnosis without valid supporting clinical findings may be considered a medical fraud by the NHI, which carries a penalty of 100-fold of the payment claimed by the treating physician or hospital. RA is a kind of major disease in Taiwan, and we can define patients with RA clearly from the Registry for Catastrophic Illness database. Because the NHIRD contains identified secondary data for research, the requirement for informed patient consent for the present study was waived off. This study was approved by the Institutional Review Board of the China Medical University (CMUH104-REC2-115). The datasets analyzed for the current study are available from the corresponding author on reasonable request.

**Selection of the Study Population**

This was a retrospective cohort study. We identified patients who were diagnosed with RA (ICD-9-CM: 714.0) from the Registry for Catastrophic Illness database. Patients with RA who received WM treatment during the period from 1 January 1997 to 31 December 2010 were selected as the cohort group, and follow-up to 31 December 2011. The patients also had to be over the age of 18 years at diagnosis. The exclusion criteria were as follows: 1) dropout from insurance, 2) diagnosis of stroke (ICD-9-CM: 430-438) or coronary artery disease (ICD-9-CM: 410-414) before the first diagnosis date of RA, and 3) a follow-up period of less than 180 days. Finally, a total of 20,483 RA patients were included in the study (Figure 1).
The participants who had traditional Chinese Medicine outpatient visits along with CHP prescription records because of RA (ICD-9-CM code: 714.0) in combination with WM between the date of initial diagnosis of RA and the endpoint were defined as the CHP group. Those patients who only received WM because of RA were assigned to the non-CHP group. The date of the first accepted CHP after the diagnosis of RA was the index date for the CHP group. The index date of the patients in the non-CHP group was the first diagnosed date of RA. Prior to matching, there were 4,960 RA patients using CHP and 14,374 patients not using CHP. We used 1:1 frequency match by age (per 5 year-groups), gender, index year, and initial diagnosis year of RA. After frequency matching, there were 4,148 RA patients in both the CHP and non-CHP groups.

**Primary Outcome**

The primary outcome was IS (ICD-9-CM: 433-438) during the 14-year follow-up with at least one inpatient claim and at least three ambulatory care claims. All eligible patients were followed up from the index date to December 31, 2011, initial diagnosis date of IS, date of withdrawal from NHI or date of death, whichever occurred first.

**Characteristics, Comorbidities, and Medication**

The sociodemographic variables included age and gender. We identified comorbidities using ICD-9-CM from the database of outpatients and inpatients. Baseline comorbidity was defined as comorbid disease which occurred before the index date, and for which there were ambulatory care claims.
for at least 3 visits or at least one inpatient claim. Based on the recommendations of the EULAR, and hypertension (ICD-9-CM: 401-405), diabetes mellitus (ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272) were considered as the covariates (Martin-Martinez et al., 2014; Agca et al., 2017). In addition, we also included baseline comorbidities which are the established risk factors for stroke, such as chronic obstructive pulmonary disease (ICD-9-CM: 491-496), end stage renal disease (ICD-9-CM: 585), and atrial fibrillation (ICD-9-CM: 427.31) as the covariates. We also considered drugs in accordance with the recommendations of the EULAR, including NSAIDs, corticosteroids, DMARDs, and TNF-antagonist prescribed after the initial diagnosis date of RA up to the endpoint of the study (Corticosteroid: beclometasone [ATC code: R03BA01], budesonide [ATC code: R03BA02], fluticasone [ATC code: R03BA05], ciclesonide [ATC code: R03BA08], formoterol [ATC code: R03AC13], and budesonide [ATC code: R03AK07]. DMARDs: tacrolimus [ATC code: L04AD02], mycophenolate mofetil [ATC code: L04AA06], azathioprine [ATC code: L04AX01], sulfasalazine [ATC code: A07EC01], hydroxychloroquine [ATC code: P01BA02], methotrexate [ATC code: L01BA01, L04AX03], leflunomide [ATC code: L04AA13], and cyclosporine [ATC code: L04AD01]. TNF-α antagonist: tanercept [ATC code: L04AB01], adalimumab [ATC code: L04AB04], rituximab [ATC code: L01XC02], and golimumab [ATC code: L04AB06]).

Statistical Analysis

The difference of basic characteristics and potential confounders between the two groups was assessed by absolute standardized mean difference instead of statistical testing because the difference is a property of the sample rather than an underlying population. The value of absolute standardized mean difference ≤0.1 indicates a negligible difference in potential confounders between the two groups. A univariate and multivariate Cox’s proportional hazard model were used to estimate the hazard ratios (HRs) and 95% CI of IS for CHP use, controlling for potential confounding factors, including age, gender, diabetes mellitus, hypertension, hyperlipidemia, COPD, ESRD, atrial fibrillation, and medication. Furthermore, we performed a multivariate Cox’s proportional hazard model to estimate the hazard ratios (HRs) and 95% CI of IS for the most commonly prescribed single herb and polyherbal formulations controlling for age, gender, diabetes mellitus, hypertension, hyperlipidemia, COPD, ESRD, atrial fibrillation, and medication.

The Kaplan–Meier method and log rank tests were performed to compare the cumulative incidence rate of IS among the two groups. We also performed subsequent subgroup analyses to examine the effect of cumulative numbers of days of CHP use. We stratified the patients in the CHP group into three subgroups: cumulative numbers of days of CHP use days <30 days, 30 to 180 days, and >180 days. In this study, SAS 9.4 (SAS Institute Inc., Cary, NC) was used for the statistical analysis.

RESULTS

After the frequency matching, the gender and age were similar between the CHP and non-CHP groups. The mean (standard deviation) age of the patients in the CHP and non-CHP groups was 46.60 (11.59) years and 46.67 (11.59) years, respectively. There is no difference between the two group with regard to comorbidities (all of the standardized mean difference < 0.1). However, the proportion of DMARDs and TNF-antagonist use in the CHP group was significantly higher than that in the non-CHP group. The mean (median) follow-up period of the CHP group is longer than that of the non-CHP group (4.37(4.92) years v.s.4.81 (4.30) years, standardized mean difference = 0.108) (Table 1).

A total of 250 patients developed IS during follow-up; the incidence rates of IS in the CHP and non-CHP group was 4.68 per 1000 person-years and 7.00 per 1000 person-years, respectively. The Kaplan–Meier analysis demonstrated that the cumulative incidence of IS in the CHP group was significantly lower than that in the non-CHP group (log-rank test, p = 0.0016) (Figure 2). Patients in the CHP group were more likely to have a lower risk of IS (crude HR: 0.67, 95% CI: 0.52–0.86) compared to their counterparts in the non-CHP group. After multivariate adjustment, the HR for the risk of IS remained the same (aHR: 0.67, 95% CI: 0.52–0.86) (Table 2).

After stratification by gender, the incidence rates of IS among the female and male patients in the CHP group were 3.96 per 1000 person-years and 9.32 per 1000 person-years, respectively. Female patients in the CHP group had a significantly lower risk of IS (aHR: 0.63, 95% CI: 0.47–0.85) compared to their counterparts in the non-CHP group. However, no significant difference was observed in this respect among the male patients (aHR: 1.35, 95% CI: 0.74–2.44) between the CHP and the non-CHP groups. In the age group of 40 to 59 years, the patients in the CHP group showed a significantly lower risk of IS compared to those in the non-CHP group (Table 2). In addition, RA patients without DM in the CHP group were associated with a lower risk of IS (aHR: 0.74, 95% CI: 0.55–0.98) compared with those in the non-CHP group. The same results were observed regarding the other baseline comorbidities, and RA patients without any comorbidity might be associated with a 0.73 to 0.69-fold lower risk of IS. Moreover, in the stratification analysis of the medication, RA patients receiving the CHP in combination with WM treatment showed a trend of reduced risk of IS compared with those receiving WM only, with the exception of RA patients taking TNF-antagonist (Table 2).

Table 3 presents the results of the subgroup analysis according to the cumulative numbers of days of CHP use among patients with RA. Compared to the non-CHP group, patients who received CHP for 30 to 180 days had a significantly lower risk of IS (aHR: 0.61, 95% CI: 0.40–0.91). Moreover, patients who use CHP >180 days showed a marginal significant lower risk of IS among patients with RA (aHR: 0.62, 95% CI: 0.38–1.00).
The five most commonly prescribed single herbs and polyherbal formulations are listed in Table 4. The most commonly used single herb was *Corydalis ambigua* Cham. & Schltdl. (Yan-Hu-Suo, n = 954, 22.9%), followed by *Spatholobus suberectus* Dunn (Ji-Xie-Teng, n = 791, 19.0%), *Cyperus rotundus* L. (Xiang-Fu, n = 675, 16.4%), *Morus alba* L. (Sang-Zhi, n = 741, 17.9%), and *Coix lacryma-jobi* L. (Yi-Yi Ren, n = 680, 16.3%). In addition, *Gui-Zhi-Shao-Yao-Zhi-Mu-Tang* (n = 1449, 34.9%) was the most commonly used polyherbal formulation, followed by *Dang-Gui-Nian-Tong-Tang* (n = 1182, 28.5%), *Shu-Jin-Huo-Xie-Tang* (n = 991, 23.9%), *Du-Huo-Ji-Sheng-Tang* (n = 696, 16.8%), and *Jia-Wei-Xiao-Yao-San* (n = 628, 15.1%). The association between prescribed polyherbal formulations and the risk of IS was explored using a Cox proportional hazard models. The results demonstrated that *Gui-Zhi-Shao-Yao-Zhi-Mu-Tang* (aHR: 0.50, 95% CI: 0.31-0.80), *Shu-Jin-Huo-Xie-Tang* (aHR: 0.35, 95% CI: 0.20-0.63), and *Du-Huo-Ji-Sheng-Tang* (aHR: 0.57, 95% CI: 0.34-0.96) were associated with a decreased risk of IS (Table 4).

**DISCUSSION**

This is the first nationwide retrospective cohort study designed to investigate the association between the risk of IS and the combined use of CHP in patients with RA. A total of 8,296 patients with RA were included in the study. There were 4,148 patients in each group after a 1:1 frequency match by gender, age, index year, and initial diagnosis year of RA. We observed an association between using CHP in combination with WM and a lower risk of IS among patients with RA (aHR for IS: 0.67 vs. non-CHP group). A possible reason for this is that the commonly used CHP, such as *Gui-Zhi-Shao-Yao-Zhi-Mu-Tang*, alleviate systemic inflammation by lowering the CRP, and erythrocyte sedimentation rate (ESR), which may decrease the progression of atherosclerosis, the main pathologic process of IS (Daily et al., 2017). Another commonly prescribed single herb, *Spatholobus suberectus* Dunn (Ji-Xie-Teng), has also been shown to suppress inflammation by decreasing TNF-α secretion (Ye et al., 2014). The findings of this study suggest that the RA patients had a decreased risk of IS which may be associated with the combined use of CHP with anti-inflammatory effects.

From the viewpoint of TCM, the etiology of RA is dampness, wind, and heat (23). In our study, *Gui-Zhi-Shao-Yao-Zhi-Mu-Tang*, which originated from the Synopsis of the Golden Chamber written by Zhang Zhong Jing in the Han Dynasty, was the most commonly prescribed polyherbal formulation (Bian, 2000). In TCM theory, *Gui-Zhi-Shao-Yao-Zhi-Mu-Tang* dispels dampness, eliminates wind, and clears heat, which is similar to the mechanism of anti-inflammatory drugs. Guo
documented that Gui-Zhi-Shao-Yao-Zhi-Mu-Tang may partially attenuate RA by reversing inflammation-immune system imbalance and regulating the signaling pathways such as those involved in the secretion of TNF-α (Guo et al., 2016). Daily et al. noted that Gui-Zhi-Shao-Yao-Zhi-Mu-Tang lowered CRP and ESR in several clinical trials (Daily et al., 2017). Moreover, single herbs in Gui-Zhi-Shao-Yao-Zhi-Mu-Tang such as Paeonia lactiflora Pall. (Shao-Yao) and Anemarrhena asphodeloides Bunge (Zhi-Mu) have an anti-inflammatory effect. Compared with patients with RA who received leflunomide alone, those who received a combination of total glucosides of peony and leflunomide showed lower levels of the CRP, ESR, and rheumatoid factor (Feng et al., 2016). This may explain the lower risk of IS among patients with RA who received a combination of CHP and WM in the present study.

Interestingly, the study finding is that female patients in the CHP group had a significantly lower risk of IS [aHR: 0.63 (95% CI: 0.47–0.85)] than those who were in the non-CHP group. However, no significant difference was observed in this respect for the in male patients. This result might be related to the patients’ lifestyle, such as tobacco use, which is a well-established risk factor for stroke. According to previous surveys of Taiwanese people, the rate of smoking was higher in males than in females (Wen et al., 2005). Additionally, smoking and

### TABLE 2 | Incidence rates, hazard ratio, and confidence intervals of ischemic stroke among rheumatoid arthritis patients with and without Chinese herbal products usage according to gender, age, comorbidities, and drug used.

| Variables | Rheumatoid Arthritis | Compared with non-CHP users |
|-----------|-----------------------|-----------------------------|
|           | Non-CHP group (n = 4148) | CHP group (n = 4148) | Crude HR (95%CI) | Adjusted HR (95%CI) |
| Event | Person years | IR† | Event | Person years | IR† | |
| Total | 146 | 20855 | 7.00 | 104 | 22211 | 4.68 | 0.67(0.52–0.86)** | 0.67(0.52–0.86)** |
| Gender | | | | | | | |
| Female | 122 | 18184 | 6.71 | 76 | 19208 | 3.96 | 0.59(0.44–0.79)** | 0.63(0.47–0.85)** |
| Male | 24 | 2671 | 8.99 | 28 | 3003 | 9.32 | 1.05(0.61–1.81) | 1.39(0.74–2.44) |
| Age group | | | | | | | |
| 18–39 | 9 | 6047 | 1.49 | 7 | 6306 | 1.11 | 0.74(0.27–1.98) | 0.73(0.26–2.01) |
| 40–59 | 96 | 12496 | 7.68 | 56 | 13331 | 4.20 | 0.55(0.39–0.76)** | 0.63(0.45–0.89)** |
| ≥60 | 41 | 2313 | 17.73 | 41 | 2574 | 15.93 | 0.89(0.59–1.38) | 0.93(0.58–1.47) |
| Baseline Comorbidty | Diabetes mellitus | | | | | | |
| No | 122 | 19274 | 6.33 | 90 | 20752 | 4.34 | 0.69(0.52–0.99)** | 0.74(0.55–0.98)** |
| Yes | 24 | 1581 | 15.18 | 14 | 1459 | 9.60 | 0.63(0.33–1.22) | 0.64(0.32–1.31) |
| Hypertension | | | | | | | |
| No | 94 | 17151 | 5.48 | 69 | 18848 | 3.66 | 0.67(0.49–0.91)* | 0.70(0.5–0.96)* |
| Yes | 52 | 3704 | 14.04 | 35 | 3363 | 10.41 | 0.74(0.48–1.13) | 0.81(0.51–1.27) |
| Hyperlipidemia | | | | | | | |
| No | 123 | 18908 | 6.51 | 81 | 20062 | 4.04 | 0.62(0.47–0.82)** | 0.69(0.51–0.92)** |
| Yes | 23 | 1947 | 11.82 | 23 | 2149 | 10.70 | 0.9(0.51–1.61) | 0.95(0.52–1.74) |
| COPD | | | | | | | |
| No | 122 | 18498 | 6.60 | 75 | 18854 | 3.98 | 0.6(0.45–0.8)** | 0.71(0.52–0.95)** |
| Yes | 24 | 2357 | 10.18 | 29 | 3357 | 8.64 | 0.86(0.5–1.48) | 0.85(0.48–1.49) |
| ESRD | | | | | | | |
| No | 142 | 20648 | 6.88 | 101 | 22072 | 4.58 | 0.67(0.52–0.86)** | 0.73(0.56–0.95)** |
| Yes | 4 | 207 | 19.35 | 3 | 139 | 21.54 | 1.04(0.23–4.64) | 0.84(0.09–8.05) |
| Atrial fibrillation | | | | | | | |
| No | 146 | 20838 | 7.01 | 104 | 22187 | 4.69 | 0.67(0.52–0.86)** | 0.73(0.56–0.95)** |
| Yes | 0 | 17 | 0.00 | 0 | 24 | 0.00 | – | – |
| Drug used | NSAID | | | | | | |
| No | 1 | 84 | 11.91 | 0 | 38 | 0.00 | – | – |
| Yes | 145 | 20771 | 6.98 | 104 | 22173 | 4.69 | 0.67(0.52–0.87)** | 0.74(0.57–0.96)** |
| Corticosteroid | | | | | | | |
| No | 134 | 20099 | 6.70 | 93 | 21019 | 4.42 | 0.66(0.51–0.86)** | 0.73(0.55–0.96)** |
| Yes | 12 | 846 | 14.18 | 11 | 1192 | 9.23 | 0.66(0.29–1.5) | 0.59(0.24–1.43) |
| DMARD | | | | | | | |
| No | 14 | 1189 | 11.78 | 4 | 537 | 7.45 | 0.63(0.21–1.93) | 0.72(0.22–2.39) |
| Yes | 132 | 19668 | 6.71 | 100 | 21674 | 4.61 | 0.69(0.53–0.98)** | 0.73(0.56–0.96)** |
| TNF-α antagonist | | | | | | | |
| No | 138 | 17579 | 7.85 | 87 | 16746 | 5.20 | 0.66(0.51–0.87)** | 0.70(0.53–0.92)** |
| Yes | 8 | 3276 | 2.44 | 17 | 5465 | 3.11 | 1.27(0.55–2.95) | 1.04(0.44–2.48) |

Adjusted HR: adjusted for CHP use, age, gender, diabetes mellitus, hypertension, hyperlipidemia, COPD, ESRD, atrial fibrillation, NSAIDs use, corticosteroid, DMARD, and TNF-α antagonist in Cox proportional hazards regression.

HR, hazard ratio; IR, incidence rates, per 1,000 person-years; CI, confidence interval; CHP, Chinese herbal products; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; NSAID, non-steroidal anti-inflammatory drugs; DMARD, disease-modifying antirheumatic drugs; TNF, tumor necrosis factor.

\*p < 0.05; **p < 0.01; ***p < 0.001.
TABLE 3 | Hazard Ratios and 95% confidence intervals of ischemic stroke risk associated with the cumulative numbers of days of CHP use among patients with rheumatoid arthritis.

| CHM prescription | Ischemic stroke | Hazard Ratio(95% CI) |
|------------------|-----------------|---------------------|
|                  | n               | No. of Event        | Crude | Adjusted† |
| Non-CHP group    | 4148            | 104                 | 1(reference) | 1(reference) |
| CHP group        |                 |                     |       |           |
| <30 days         | 1966            | 57                  | 0.83(0.61–1.12) | 0.84(0.64–1.20) |
| 30–180 days      | 1380            | 28                  | 0.53(0.35–0.79)** | 0.61(0.40–0.91)* |
| >180 days        | 802             | 19                  | 0.57(0.35–0.92)* | 0.62(0.38–1.00) |

Crude HR* represented relative hazard ratio; Adjusted HR† represented adjusted hazard ratio: mutually adjusted for age, gender, diabetes mellitus, hypertension, hyperlipidemia, COPD, ESRD, atrial fibrillation, NSAID uses, corticosteroid, DMARD, and TNF-antagonist in Cox proportional hazard regression.

TABLE 4 | Hazard Ratios and 95% confidence intervals of ischemic stroke risk associated with the type of single herbs and polyherbal formulations used among patients with rheumatoid arthritis.

| CHM prescription | Ischemic stroke | Hazard Ratio(95% CI) |
|------------------|-----------------|---------------------|
|                  | n               | No. of Event        | Crude* | Adjusted† |
| Non-CHP group    | 4148            | 104                 | 1(reference) | 1(reference) |
| CHP group        |                 |                     |       |           |
| Single herb      |                 |                     |       |           |
| 1. Corydalis ambigua Cham. & Schltld. (Yen-Hu-So) | 954 | 29 | 0.78(0.52–1.16) | 0.92(0.61–1.38) |
| 2. Spatholobus suberectus Dunn (Ji-Xie-Teng) | 791 | 22 | 0.69(0.44–1.08) | 0.81(0.52–1.29) |
| 3. Cyperus rotundus L. (Pao-Fu-Tzu) | 675 | 18 | 0.70(0.43–1.14) | 0.87(0.53–1.44) |
| 4. Morus alba L. (Sang-Chih) | 741 | 21 | 0.71(0.45–1.12) | 0.84(0.52–1.33) |
| 5. Coix lacryma-jobi L. (Yi-Yi Jen) | 680 | 19 | 0.71(0.44–1.14) | 0.84(0.51–1.36) |
| Polyherbal formulation |                 |                     |       |           |
| 1. Gui-Zhi-Shao-Yao-Zhi-Mu-Tang | 1449 | 21 | 0.44(0.28–0.70)** | 0.50(0.31–0.80)** |
| 2. Dang-Gui-Nian-Tong-Tang | 1182 | 35 | 0.61(0.42–0.89)** | 0.71(0.48–1.03) |
| 3. Shu-Jin-Huo-Xie-Tang | 991 | 13 | 0.32(0.18–0.56)** | 0.35(0.20–0.65)** |
| 4. Du-Huo-Ji-Sheng-Tang | 696 | 16 | 0.54(0.32–0.91)*** | 0.57(0.34–0.96)* |
| 5. Jia-Wei-Xiao-Yao-San | 628 | 18 | 0.72(0.44–1.17) | 1.06(0.64–1.76) |

Crude HR* represented relative hazard ratio; Adjusted HR† represented adjusted hazard ratio: mutually adjusted for CHP use, age, gender, diabetes mellitus, hypertension, hyperlipidemia, COPD, ESRD, atrial fibrillation, NSAID, corticosteroid, DMARD, and TNF-antagonist usage in Cox proportional hazard regression.

CI, confidence interval; CHP, Chinese herbal products; COPD, chronic Obstructive Pulmonary Diseases; ESRD, end stage renal disease; NSAID, non-steroidal anti-inflammatory drugs; DMARD, disease-modifying antirheumatic drugs; TNF, tumor necrosis factor.

*p < 0.05, **p < 0.01, ***p < 0.001.

obese male tend to engage in irregular exercise (Lin et al., 2016). This then establishes the factors for stroke that might influence this study’s results (Pearson et al., 2002; Boehme et al., 2017).

Table 2 presents that there was no significant difference between the two groups in risk of IS among the RA patients with any kind of comorbidity which is the main risk factor for IS. However, a reduced risk of IS was observed in the CHP group among RA patients without any kind of comorbidity. A possible explanation for this is that the baseline comorbidities, major risk factors for IS, may reduce the efficacy of CHP and exert an influence on the risk of IS. Hypertension, diabetes, hyperlipidemia, chronic obstructive pulmonary disease, end stage renal disease, and atrial fibrillation are thought to be the independent risk factors for IS with 2- to 3-fold increased risk in stroke (Boehme et al., 2017). Possible mechanisms leading to stroke are chronic systemic inflammation (Austin et al., 2016; Chen R. et al., 2016; Jimenez et al., 2016; Nayak-Rao and Shenoy, 2017; Menet et al., 2018). Inflammation plays an important role in the development of the atherosclerotic plaque and the main pathologic process of IS. Although several commonly prescribed CHP have anti-inflammation effects, the chronic inflammation among RA patients with any kind of comorbidity might be too severe to be reversed. Therefore, there was no association between protective effect against IS of CHP and the risk of IS among RA patients with comorbidities. In the aspect of medication, RA patients receiving CHP in combination with DMARDs had a lower risk of IS compared to those receiving WM only. However, there is no significantly lower risk of IS among RA patients receiving CHP in combination with TNF-antagonist compared to those receiving WM only. The reason might be because the systemic inflammation of RA patients receiving TNF-antagonist are too severe to be alleviated. Doctors usually prescribe TNF-antagonist to treat RA patients due to high disease activity, early joints erosion, or high level of rheumatoid factor indicate higher grade of inflammation and disease severity than those taking DMARDs.
| Name | Active compounds | Function | Reference |
|------|------------------|----------|-----------|
| Single herb | Corydalis ambigua Cham. & Schltdl. (Yan-Hu-Suo) | Corynoline, Acetylcorynoline,d-corydal, dl-tetrahydropalmatine, Protopine, Tetrahydrocoptisine, dl-tetrahydroCoptisine, d-corybulbine, Allocryptopine | Pain tolerance↑ Anti-hypertension Anti-inflammation | (Zhou et al., 2016; Zhou et al., 2019) |
| | Spatholobus suberectus Dunn (Ji-Xie-Teng) | Jixuetengstero, Friedelin, Friedelinsterol, Taraxerone, β-Sitosterol, Stigmasterol, Campesterol | Anti-inflammation Anti-oxidant effects Anti-viral effects Immunomodulatory | (Fu et al., 2017; Pang et al., 2011) |
| | Cyperus rotundus L. (Xiang-Fu) | α-longipinane, β-selinene, Cyperene, Caryophyllene oxide | Anti-nociceptive effects Anti-inflammatory Anti-oxidant effects Anti-lipidemic, | (Imam and Sumi, 2014; Pirzada et al., 2015) |
| | Morus alba L. (Sang-Zhi) | Morin, Oxyresveratrol, Mulberin, Mulbel-Cochromene, Cyclomulberin, Cyclomulbel-rochromene | Anti-inflammation Anti-oxidant Anti-tumour activities Anti-hyperlipidemic, | (Bachewal et al., 2018; Park et al., 2016; Li et al., 2015) |
| | Coix lacryma-jobi L. (Yi-Yi-Ren) | Coixol, Coixenolide, Myristic acid | Anti-inflammation Anti-oxidant effects Anti-tumour activities | (Seo et al., 2000) |
| Polyherbal formulation | Paeonia lactiflora Pall. (Bai-Shao) | 9.6% | Morning stiffness ↓ CRP↓ | (Efthimiou and Kukar, 2010; Ye et al., 2014) |
| | Atractylodes macrocephala Koidz. (Bai-Zhu) | 16.1% | RSR↓ RA factor↓ | |
| | Anemarrhena asphodeloides Bge. (Zhi-Mu) | 12.9% | | |
| | Saposhnikovia divaricata (Turcz.) Schischk. (Fang-Feng) | 12.9% | | |
| | Glycyrrhiza uralensis Fisch. ex DC. (Gann-Cao) | 6.5% | | |
| | Cinnamomum cassia (L.) J.Presl (Gui-Zhi) | 6.5% | | |
| | Ephedra sinica Stapf (Ma-Huang) | 6.5% | | |
| | Zingiber officinale Roscoe (Sheng-Jiang) | 6.5% | | |
| | Dang-Gui-Nian-Tong-Tang | Artemisia capillaris Thunb. (Yin-Chen) | 10.6% | Not available | |
| | Notopterygium incisum K.C.Ting ex H.T.Chang (Qiang-Huo) | 10.6% | | |
| | Saposhnikovia divaricata (Turcz.) Schischk. (Fang-Feng) | 4.6% | | |
| | Actaea heracleefola (Kom.) J.Compton (Sheng-Ma) | 4.6% | | |
| | Pueraria lobata (Wild.) Ohwi (Ge-Gen) | 6.0% | | |
| | Atractylodes lancea (Thumb.) DC. (Cang-Zhu) | 10.6% | | |
| | Atractylodes macrocephala Koidz. (Bai-Zhu) | 4.6% | | |
| | Glycyrrhiza uralensis Fisch. ex DC. (Gan-Cao) | 6.0% | | |
| | Scutellaria baicalensis Georgi (Huang-Qin) | 4.6% | | |
| | Sophora flavescens At. (Ku-Shen) | 6.0% | | |
| | Anemarrhena asphodeloides Bge. (Zhi-Mu) | 6.0% | | |
| | Angelica sinensis (Oliv.) Diels (Dang-Gui) | 6.0% | | |
| | Polyposus umbellatus (Pers.) Fries (Zhu-Ling) | 4.6% | | |
| | Alstonia plantago-aquatica subsp. orientale (Sam.) Sam. (Ze-Xie) | 6.0% | | |
| | Shu-Jin-Huo-Xie-Tang | Angelica sinensis (Oliv.) Diels (Dang-Gui) | 7.2% | Interleukin 2 production ↓ | (Imam and Sumi, 2014) |
| | Ligusticum chuanxiong Hort. (Chuan-Qiong) | 3.7% | | |
| | Paeonia lactiflora Pall. (Bai-Shao) | 9.1% | | |
| | Rehmannia glutinosa Libosch. (Di-Huang) | 7.2% | | |
| | Atractylodes lancea (Thumb.) DC. (Cang-Zhu) | 7.2% | | |

(Continued)
only (Albrecht and Zink, 2017). Hence, the association between a lower IS risk and receiving the CHP treatment in combination with WM among severe RA patients was not significant.

In the CHP group, patients with cumulative numbers of days of CHP use between 30 and 180 days were found to have a lower risk of IS than those whose cumulative numbers of days of CHP use <30 days. A possible explanation for this is that CHP requires 30-180 days to achieve a steady effect in patients with RA. The cumulative number of days of CHP use was similar to the treatment duration of methotrexate recommended by the European League Against Rheumatism (Smolen et al., 2017). Moreover, the results obtained for the minimum number of days of CHP use were consistent with those of previous randomized controlled trials. Patients with RA taking *Paeonia lactiflora* Pall. (Shao-Yao) extract in combination with treatment with leflunomide and methotrexate for 24 weeks had lower CRP levels and ESR (Chen et al., 2013). Additionally, after 12 to 24 weeks of treatment with *Tripterygium wilfordii* Hook.f in combination with methotrexate, there was an improvement in the level of CRP (Lv et al., 2015). Furthermore, several randomized controlled trial about the efficacy of Gui-Zhi-Shao-Yao-Zhi-Mu-Tang with WM showed that after taking Gui-Zhi-Shao-Yao-Zhi-Mu-Tang with WM for 4-12 weeks, there was a significant decrease in ESR, RA factor, and CRP (Dai et al., 2017). The Pathological mechanisms of RA are characterized by chronic systemic inflammation, and patients using CHP for 30-180 days may achieve an improved anti-inflammatory effect in terms of reducing their risk of IS.

Another major finding of this study is that the commonly prescribed polyherbal formulations, such as Gui-Zhi-Shao-Yao-Zhi-Mu-Tang, Shu-Jin-Huo-Xie-Tang, Du-Huo-Ji-Sheng-Tang, have been found to lower the risk of IS (Table 4). A possibly explanation is that the polyherbal formulations may suppress chronic inflammation in patients with RA. The function,
ingredients, and the percentage of every single herb of the top 5 most commonly prescribed polyherbal formulations were presented in Table 5. Daily et al. have reported that Gui-Zhi-Shao-Yao-Zhi-Mu-Tang may lower the levels of the CRP and the ESR in patients with RA (Daily et al., 2017). Previous research has demonstrated that more than 50% of ingredients contained in Gui-Zhi-Shao-Yao-Zhi-Mu-Tang have anti-inflammatory effects with lowering of the level of rheumatoid factor or suppressing the production of TNF-α or IL-6; these included Paonia lactiflora Pall. (Bai-Shao), Anemarrhena asphodeloides Bge. (Zhi-Mu), Saposhnikovia divaricata (Turcz.) Schischk. (Fang-Feng) and Zingiber officinale Roscoe (Sheng-Jiang) (Chen et al., 2013; Kong et al., 2013; Funk et al., 2016). Although there was only a Chinese study presented that Shu-Jin-Huo-Xie-Tang can lower the production of lympocytes in an experimental RA model (Peng et al., 2012; Kong et al., 2013; Funk et al., 2016; Hung and Wu, 2016; Liu et al., 2016; Li et al., 2016). In addition, Du-Huo-Ji-Sheng-Tang has been claimed to mediate an anti-inflammatory effects by promoting lymphatic drainage function in TNF-Tg mice (Chen Y. et al., 2016). Certain single herbs in Du-Huo-Ji-Sheng-Tang also have an anti-inflammatory effect, such as Saposhnikovia divaricata (Turcz.) Schischk. (Fang-Feng) and Zingiber officinale Roscoe (Sheng-Jiang), have been shown to suppress the expression of several inflammatory cytokines in an experimental RA model (Peng et al., 2012; Kong et al., 2013; Funk et al., 2016; Hung and Wu, 2016; Liu et al., 2016; Li et al., 2016).

In conclusion, the use of the date of admission to the hospital when accepting CHP as the index date in the CHP group helps to avoid bias whereby patients with a longer stroke-free period of time tend to use CHP. Third, we performed a subgroup analysis based on the number of cumulative days of CHP usage for clinical use.

Second, the use of the date of first accepted CHP as the index date in the CHP group helps to avoid bias whereby patients with a longer stroke-free period of time tend to use CHP. Third, we performed a subgroup analysis based on the number of cumulative days of CHP usage for clinical use.

Several limitations of the present study need to be considered. Data pertaining to life style, smoking, drinking, obesity, and body mass index are unavailable from the NHIRD. Similarly, data pertaining to disease activity and disease severity were unavailable, although all of them are known risk factors for IS (Dhillon and Liang, 2015). We performed a 1:1 frequency match and used a Cox proportional hazard model to eliminate the potential effect of confounding factors. Second, NHIRD only covers CHP prescribed by licensed TCM physicians. Patients who resorted to over-the-counter use of CHP may not have been included in the study sample, which is likely to have led to an underestimation of the percentage of CHP usage. Third, safety of prescribed polyherbal formulations are not available. Certain single herbs contained in the polyherbal formulations were reported to cause adverse reactions. Aconitum carmichaelii Debx. (accounts for 6.5%), contained in Gui-Zhi-Shao-Yao-Zhi-Mu-Tang, might cause palpitation, hypotension, and arrhythmia due to aconitine alkaloids. Asarum sieboldii Miq. (accounts for 6.5%), one of the single herb in the Du-Huo-Ji-Sheng-Tang, might lead to renal failure, tubulointerstitial fibrosis, and urothelial cancer owing to aconitine alkaloids. Although, the toxic compounds of the certain single herbs might result in harmful effects, Daily and Hsieh reported that no severe adverse events and drug reactions are observed after taking Gui-Zhi-Shao-Yao-Zhi-Mu-Tang and Du-Huo-Ji-Sheng-Tang 4 to 20 weeks (Hsieh et al., 2010; Daily et al., 2017).

CONCLUSION

This study demonstrated the association between a decreased IS risk and receiving CHP treatment in combination with WM in RA patients, particularly those who used CHP for more than 30 days. Our findings suggest that Gui-Zhi-Shao-Yao-Zhi-Mu-Tang, Shu-Jin-Huo-Xie-Tang, and Du-Huo-Ji-Sheng-Tang might be associated with a lower risk of IS. A further randomized control trial is required to clarify the casual relationship between these results.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

AUTHOR CONTRIBUTIONS

H-SS was responsible for the study’s conception and design, reviewing and interpreting the data, and drafting the manuscript. N-HH was responsible for modifying the study design, interpreting the data, and the critical revision. J-HC contributed to the collection and analysis of the data. H-SS, N-HH, and J-HC were responsible for the final approval of the revised manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University Hospital, Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.
Seo, W. G., Pae, H. O., Chai, K. Y., Yun, Y. G., Kwon, T. H., Chung, H. T., et al. (2014). Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. *Semin. In Arthritis Rheum.* 44, 1–8. doi: 10.1016/j.semarthrit.2014.01.002

Menet, R., Bernard, M., and ElAli, A. (2018). Hyperlipidemia in Stroke Pathobiology and Therapy: Insights and Perspectives. *Front. In Physiol.* 9, 488. doi: 10.3389/fphys.2018.00488

Michalsen, A. (2013). The role of complementary and alternative medicine (CAM) in rheumatology—it’s time for integrative medicine. *J. Rheumatol.* 40, 547–549. doi: 10.3899/jrheum.130107

Nadareishvili, Z., Michaud, K., Hallenbeck, J. M., and Wolfe, F. (2008). Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. *Arthritis Rheum.* 59, 1090–1096. doi: 10.1002/art.23935

Nayak-Rao, S., and Shenoy, M. P. (2017). Stroke in patients with chronic kidney disease:... How do we Approach and Manage it? *Indian J. Nephrol.* 27, 167–171. doi: 10.4103/0971-4065.202405

Pang, J., Guo, J. P., Jin, M., Chen, Z. Q., Wang, X. W., and Li, J. W. (2011). Antiviral effects of aqueous extract from Spatholobus suberectus Dunn. against coxsackievirus B3 in mice. *Chin. J. Integr. Med.* 17, 764–769. doi: 10.1007/s11655-011-0642-M

Park, G. S., Kim, J. K., and Kim, J. H. (2016). Anti-inflammatory action of ethanolic extract of Ramulus mori on the BLT2-linked cascade. *MBB Rep.* 49, 232–237. doi: 10.5483/bmbrep.2016.49.4.002

Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., et al. (2002). AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guideline to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. *American Heart Association Science Advisory and Coordinating Committee. Circulation* 106, 388–391. doi: 10.1161/01.CIR.0000054612.26458.B2

Peng, C., Perera, P. K., Li, Y. M., Fang, W. R., Liu, L. F., and Li, F. W. 2012 Anti-inflammatory effects of Clematis chinensis Osbeck extract (AR-6) may be associated with NF-kB, TNF-α, and COX-2 in collagen-induced arthritis in rat. *Rheumatol. Int.* 32, 3119–3125, doi: 10.1007/s00296-011-2083-8

Pirzada, A. M., Ali, H. H., Naem, M., Latif, M., Buhari, A. H., and Tanveer, A. (2015). Cyperus rotundus L.: traditional uses, phytochemistry, and pharmacological activities. *J. Ethnopharmacol.* 174, 540–560. doi: 10.1016/j.jep.2015.08.012

Rouille, C., Richer, V., Starmino, T., McCourt, C., McFarlane, A., Fleming, P., et al. (2015). The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann. Rheumatic Dis.* 74, 480–489. doi: 10.1136/annrheumdis-2014-206624

Salliot, C., and van der Heijde, D. (2009). Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann. Rheumatic Dis.* 68, 1100–1104. doi: 10.1136/ard.2008.093690

Sattar, N., McCoy, D. W., Capell, H., and McInnes, I. B. (2003). Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. *Circulation* 108, 2957–2963. doi: 10.1161/01.cir.0000099844.31524.05

Seo, W. G., Pae, H. O., Chai, K. Y., Yun, Y. G., Kwon, T. H., Chung, H. T., et al. (2000). Inhibitory effects of methanol extract of seeds of Job’s Tears (Coix lachryma-jobi L. var. ma-yuen) on nitric oxide and superoxide production in RAW 264.7 macrophages. *Immunopharmacol. Immunotoxicol.* 22, 545–554.

Shu, H., Arita, H., Hayashida, M., Zhang, L., An, K., Huang, W., et al. (2010). Anti-hypersensitivity effects of Shu-jing-huo-xue-tang, a Chinese herbal medicine, in CCI-neuropathic rats. *J. Ethnopharmacol.* 131, 464–470. doi: 10.1016/j.jep.2010.07.004

Smolen, J. S., Landewe, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., et al. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann. Rheumatic Dis.* 76, 960–977. doi: 10.1136/annrheumdis-2016-210715

Soeken, K. L., Miller, S. A., and Ernst, E. (2003). Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. *Rheumatol. (Oxford)* 42, 652–659. doi: 10.1093/rheumatology/keg183

Solomon, D. H., Karlson, E. W., Rimm, E. B., Cannuscio, C. C., Mandl, L. A., Manson, J. E., et al. (2003). Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 107, 1303–1307. doi: 10.1161/01.CIR.0000054612.26458.B2

Tam, H. W., Chen, C. M., Leong, P. Y., Chen, C. H., Li, Y. C., Wang, Y. H., et al. (2018). Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. *Int. J. Rheumatic Dis.* 21, 1591–1599. doi: 10.1111/1756-185x.13267

Wang, Q., Kuang, H., Su, Y., Sun, Y., Feng, J., Guo, R., et al. (2013). Naturally derived anti-inflammatory compounds from Chinese medicinal plants. *J. Ethnopharmacol.* 146, 9–39. doi: 10.1016/j.jep.2012.12.013

Wen, C. P., Levy, D. T., Cheng, T. Y., Hsu, C. C., and Tsai, S. P. (2005). Smoking behaviour in Taiwan. 2001. Tob. Control 14 Suppl 1, i51–i55. doi: 10.1136/tc.2004.008011

Ye, H., Wu, W., Liu, Z., Xie, C., Tang, M., Li, S., et al. (2014). Bioactivity-guided isolation of anti-inflammation flavonoids from the stems of Millettia dielesi Dav. *Fitosanitariya* 95, 154–159. doi: 10.1016/j.fitote.2014.03.008

Zhang, C., Jiang, M., and Lu, A. P. (2011). Evidence-based Chinese medicine for rheumatoid arthritis. *J. Tradit. Chin. Med.* 31, 152–157. doi: 10.1007/s10524-013-0031-9

Zhou, H. H., Wu, D. L., Gao, L. Y., Fang, Y., and Ge, W. H. (2016). L-Tetrahydrodipalmitic aldehyde alleviates mechanical hyperalgesia in models of chronic inflammatory and neuropathic pain in mice. *Neuroreport* 27, 476–480. doi: 10.1097/WRN.0000000000000560

Zhou, Y. Z., Zhao, W. R., Shi, W. T., Xiao, Y., Ma, Z. L., Xue, J. G., et al. (2019). Endothelial-dependent and independent vascular relaxation effect of tetrahydrodipalmitic on rat aorta. *Front. Pharmacol.* 10, 336. doi: 10.3389/fphar.2019.00336

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor and reviewer RH declared their involvement as co-editors in the Research Topic, and confirm the absence of any other collaboration.

Copyright © 2020 Shen, Chiang and Hisung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.